ClinicalTrials.gg

Program

GW906

A development code. Also written as “GW906 injection”.

Its studies are mostly in Hypertension, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 2, since Sep 17, 20264 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals43 open or runningphase 2since Sep 17, 2026Sep 17, 2026Oct 2027phase 2 · NCT07835984

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2026First study: phase 1 study in HypertensionFirst studyNCT07884461 · 40 enrolled · China
  2. Sep 17, 20262 phase 2 studies in HypertensionNCT07835984, NCT07835971
  3. Sep 18, 2026No phase study in HypertensionNCT07879755 · 1,500 planned · China

Ahead

  1. Oct 2027Primary completion: phase 2 study in HypertensionNCT07835984
  2. Jan 30, 2029Primary completion: no phase study in HypertensionNCT07879755

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07879755Hypertension · China–RecruitingJan 30, 20291,500
NCT07884461Hypertension · China1CompletedAug 24, 202640
NCT07835984Hypertension · China2Not yet recruitingOct 2027560
NCT07835971Hypertension · China2Active, not recruitingSep 15, 2026319

How it is read

Names in the registry

  • “GW906”, 3 entries
  • “GW906 injection”, 1 entry

Codes read as this program: GW906.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.